Medicxi Ventures (UK) LLP, operating as Medicxi, is a London-based venture capital firm specializing in life sciences investments. Established in 2016 by the former life sciences team from Index Ventures, the firm focuses on biotech and pharmaceuticals, backing companies from early discovery through to clinical proof-of-concept and beyond.
Medicxi employs an "asset-centric" investment strategy, creating and funding virtual startups around promising therapeutic assets to accelerate development of novel treatments for unmet medical needs. It has raised multiple funds totaling over €2 billion, with backing from major players including GlaxoSmithKline, Johnson & Johnson Innovation, Novartis, and Verily. The firm maintains offices in London, Geneva, and Jersey.
Portfolio successes include exits like Vicebio (acquired by Sanofi), Versanis (Eli Lilly), and Centessa Pharmaceuticals, alongside ongoing support for biotechs in oncology, neurology, and immunology.
To provide comprehensive coverage, we aggregate data and news under the name Medicxi Ventures, encompassing the following company names, divisions, and related entities:
Medicxi.
This list encompasses current and former names, alternate names, and key divisions associated with Medicxi Ventures, ensuring you can easily find all relevant information under a single, unified profile.
